Philip T. Sager, M.D., Joins NewCardio's Scientific Advisory Board
December 22nd, 2008
2008 DEC 22 -- NewCardio, Inc., (BULLETIN BOARD: NWCI) a cardiac diagnostic and services company, announced that Philip T. Sager, M.D., FACC, FAHA, FHRS, has joined the Company's Scientific Advisory Board.
Dr. Sager is currently the Chief Medical Officer of CardioDX, a cardiovascular genomic diagnostics company focused on serving cardiologists by offering clinically validated, actionable genomic diagnostics. Prior to joining CardioDx, he was Executive Director at AstraZeneca Inc. where he was responsible for the medical and scientific leadership of several worldwide pharmaceutical development programs and the corporate strategies for QT/CV Safety issues in drug development. Before joining AstraZeneca, Dr. Sager was Medical Director for the Schering-Plough Research Institute where he played key roles in the development and NDA approval of drugs to treat hypercholesterolemia. He joined the pharmaceutical industry after 11 years at the UCLA School of Medicine where he was a tenured faculty member in cardiology. He is a Fellow of the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society. Dr. Sager is Co-Chair of the Scientific Oversight Committee and Executive Committee member of the FDA-sponsored Cardiac Safety Research Consortium and is a member of the International Committee on Harmonization E14 Expert Working Group. Dr. Sager received B.S. degrees from the Massachusetts Institute of Technology, and his M.D. from Yale University, where he also completed medical residency, cardiology fellowship, and a cardiovascular electrophysiology fellowship. He has published more than 150 scientific manuscripts and abstracts.
Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "Dr. Sager is a recognized leader in the field of Electrophysiology and brings vast knowledge regarding the interests and demands of pharmaceutical customers to our Scientific Advisory Board. His experience in clinical and drug development settings, and his expertise in drug cardiac safety issues, will prove invaluable to NewCardio as we advance our platform technology and build solutions to address a wide range of cardiology issues."
Dr. Sager added, "NewCardio's unique three-dimensional ECG platform promises to be one of the most important innovations to electrocardiology in many decades. This technology has the potential to support a wide-range of solutions, which can save lives, improve quality of care, accelerate drug development and deliver precise, easy-to-understand information. I am excited to participate in this important effort and look forward to contributing to the development of this platform technology."
Keywords: AstraZeneca, Cardiology, Cardiovascular, Diagnostics, Drug Development, FDA, Hypercholesterolemia, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Regulatory Actions, Schering-Plough Corporation, Therapy, Treatment, U.S. Food and Drug Administration, NewCardio Inc.
This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2008, Biotech Business Week via NewsRx.com.
